Abstracts / The Breast 20 (2011) S12–S55 S49

benefit rate (CR+PR+SD>6mos) (<1yr, 23.7%; 1-3yrs, 18.9%; >3-5yrs,15.9%; >5yrs, 28.6%). The proportion of patients reporting stable diseasewas also similar (<1yr, 42.11%; 1-3yrs, 44.26%; >3-5yrs, 47.56%; >5yrs,44.44%).Overall survival and independently-reviewed assessment of progression-free survival demonstrated no clinical differences in survival rates (p¼0.56and p¼0.73, respectively) between the stratified treatment groups.The incidence of adverse events was similar across all eribulin mesylatetreatment groups, with no significant differences in the incidence of Grade3/4 adverse events of leukopenia, lymphopenia, neutropenia, febrileneutropenia, and neuropathy.In this exploratory, post-hoc analysis, the clinical response to eribulinmesylate in patients with mBC appears independent of time to firstmetastatic event. Additional studies are required to confirm these findingsin less heavily pretreated patients.

PO108

A CASE REPORT OF METASTATIC BREAST CANCER SUCCESSFULLYTREATED WITH LAPATINIB PLUS CAPECITABINE THERAPY

Sara Meireles, Andreia Costa, Matilde Salgado, Daniela Almeida, GabrielaPinto, Margarida DamascenoCentro Hospitalar São João, Porto, Portugal

Background: Lapatinib is a dual tyrosine-kinase inhibitor which targetsboth human epidermal growth factor receptor 2 (HER2) and epidermalgrowth factor receptor (EGFR) tyrosine-kinases. Lapatinib showedpromising results both in trastuzumab-naïve and in pretreated HER2positive advanced breast cancer and has the advantage of beingadministered orally. It has been showed that lapatinib plus capecitabineis superior to capecitabine alone in HER2 positive advanced breastcancer patients previously treated with anthracycline, taxane andtrastuzumab.Case-report: A 34-year-old woman was admitted to our hospital inJanuary 2008 with a palpable nodule in the lower inner quadrant of theright breast (about 5 cm) and an enlarged homolateral axillary lymphnode. The biopsies from the right breast nodule and axillary lymph nodeshowed an invasive ductal carcinoma. Immunohistochemical (IHC) stain-ing of estrogen and progesterone receptors was negative but HER2 statusby FISH was positive. According to TNM classification, it was pT2N1M0. Itwas decided to start neoadjuvant chemotherapy with AC + TH schedule(doxorubicin 60 mg/m2 day 1 and cyclophosphamide 600 mg/m2 day 1every 21 days for 4 cycles plus docetaxel 100 mg/m2 every 21 days for 4cycles with concurrent trastuzumab 8mg/kg followed by 6 mg/kg) withgood clinical response. Six months later she underwent radical modifiedmastectomy with axillary lymph nodes dissection and immediate breastreconstruction. Histological examination confirmed a 30 mm, grade 3,invasive ductal carcinoma with dermal and lymphatic invasion, and onemetastatic lymph node (1/12 nodes). Computed tomography scans (CT)and bone scintigraphy didn't reveal any secondary lesion. She wassubmitted to radiotherapy and she completed one year treatment withtrastuzumab in March 2009. She had no recurrence until April 2010, whenshe complained of sternal pain and dyspnea. CT showed carcinomatouslymphangitis and multiple liver metastasis. Bone scintigraphy revealedmultifocal osteoblastic bone metastasis. Chemotherapy with lapatinib1250 mg/day on days 1-21 plus capecitabine 2000 mg/m2/day on days 1-14 every 3 weeks and zoledronic acid was started. Capecitabine dose wasreduced 25% due to hand - foot syndrome (grade 3). After one year oftherapy, she has complete response of lung disease, partial response ofliver disease and stabilization of bone metastasis. No other side effects oftherapy were recorded and the patient shows an ECOG performance statusof 0.Conclusion: Our case has no evidence of disease progression after four-teen months of lapatinib plus capecitabine therapy, which is significantlylonger than the median of 6 months that it has been reported by the mostimportant published trial. This supports the efficacy and good safetyprofile of this treatment in HER2 positive advanced and metastatic breastcancer.

PO109

EFFECTIVE MANAGEMENT OF MALIGNANT PLEURAL EFFUSION INADVANCED BREAST CANCER PATIENTS BY INTRAPLEURALCHEMOTHERAPY WITH CISPLATIN AND GEMCITABINE

Elena Shakhnovich1, Elena Chelnokova 1, Oleg Kerbikov 2, Alexander Shulga 3

1City Khimki Hospital, Khimki, Moscow Region, Russia2Russian State Medical University, Moscow, Russia3 Fereral State Outpatient Clinic #119, FederalMedical-Biological Agency, Khimki,Moscow Region, Russia

Lung metastasis and malignant pleural effusion are common complica-tions of the advanced breast cancer (ABC) and may cause a significantdecrease in life quality in ABC patients. The intrapleural chemotherapy(IPC) has an advantage of simultaneously treating the malignancy andmanaging the effusion.The aim of this study was to evaluate the safety and efficacy of IPC withCisplatin and Gemcitabine in patients with ABC with lung metastasis andsevere pleural effusion.Materials and methods: 5 patients (pts) (median age 59 range 53-70)were prospectively enrolled into the study. All pts had ABC (T2N0-1M0)and all pts underwent neoadjuvant therapy consisting of chemotherapy(schemes FAC and AC) followed by surgical intervention and hormonetherapy. Median progression-free survival was 11.4 months (range 3-18).After relapse all pts developed lung, bone and liver metastasis. Thesubsequent treatment consisted of radiation therapy, chemotherapy andpalliative surgery (surgical removal of brain metastasis) in one case. Thechemotherapy comprised of Taxanes, Platinum-based regimens, Gemci-tabine, Capecitabine, Vinorelbine and Epirubicin hydrochloride. Themedian number of chemotherapy lines was 4 (range 2-7). The diseaseprogressed and periods of stabilization were short (1-2 months). After thelast administration of chemotherapy, all pts developed malignant pleuraleffusion. IPC consisting of a single dose of Cisplatin (50 mg) plus Gemci-tabine (1000 mg) was administrated into pleural space via a chest tube. Inthis study, we evaluated toxicity and response, measured bi-weekly duringthe first month and monthly thereafter.Results: Complete response (no recurrence of effusion) was achieved in 4pts, and a partial response (70% and greater decrease of the amount ofeffusion) was observed in one patient. The median duration of responsewas 5.6 months (range 3-8). No serious complications were reported.Conclusion: Intrapleural chemotherapy with Cisplatin and Gemcitabine isa viable treatment option in patients with malignant effusion from ABC.

PO110

EPIDEMIOLOGICAL, GENETIC, HISTOLOGICAL AND CLINICAL ASPECTSOF BREAST CANCERS IN POPULATION OF CZECH WOMEN

Marek Svoboda, Jiri Navratil, Pavel Fabian, Eva Machackova, MarieNavratilova, Ondrej Slaby, Peter Grell, Jiri Sedo, Lenka Foretova, RudolfNenutil, Rostislav VyzulaMasaryk Memorial Cancer Institute, Brno, Czech Republic

Introduction: In 2007, 6500 new cases of breast cancer (BC) were diag-nosed in the Czech Republic (incidence of 123 cases (69.8 ASR-W) per 100000). The aim of our research was to analyse available epidemiologicaldata in the context of new molecular, genetic and biological knowledge ofthe disease.Methods: Epidemiological data (Czech Cancer Registry) on BC incidenceand mortality in the Czech Republic since 1977 were compared with theresults of retrospective analyses of 3 cohorts: 1) 2100 families tested forthe BRCA1 and BRCA2 gene mutation, 2) 515 consecutive BC patientsdiagnosed in our hospital in 2009, and 3) 1334 BC patients treated in ourhospital between 2005 and 2009.Results: The cumulative risk of breast cancer in Czech women (0-74 years)is 6-7%. Luminal-A type form the largest group representing 72.7% of all BCcases, followed by HER-2 positive carcinoma (14.6%) and triple negativecarcinoma (TNC, 12.7%). Although TNC showed the largest proliferation